Complete report $11,500.  DataPack (test volumes, sales forecasts, supplier shares) $7,500. “2015-2019 Clinical Chemistry and Immunodiagnostics Testing in US Hospitals, Commercial Laboratories and Point-of-Care/POC Locations” is a new strategic analysis of major business opportunities emerging in the US clinical chemistry and immunodiagnostic hospital, commercial and point-of-care/POC markets during the next five years.  The report explores future trends in the US market; provides estimates of the specimen, test and sales volumes, as well as major suppliers’ sales and market shares; compares features of leading analyzers; profiles key competitors; and identifies specific product and marketing opportunities emerging during the next five years. The report provides five-year volume and sales forecasts for over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein and abused drug assays performed in hospitals, commercial laboratories, physician offices,  ER, OR, ICU, cancer clinics, ambulatory care centers, surgery centers, nursing hones, and birth centers, including controls, calibrators and consumables. Rationale The clinical chemistry and immunodiagnostic markets are undergoing significant transformation, caused by convergence of new and more stringent regulations; advances in diagnostic technologies, system... Research Beam Model: Research Beam Product ID: 322027 0 USD New
2015-2019 Clinical Chemistry and Immunodiagnostic Testing in the US Hospitals, Commercial Laboratories and Point-of-Care/POC Locations

Toll Free : +1 (800)910-6452

 
 
PURCHASE OPTIONS
 

2015-2019 Clinical Chemistry and Immunodiagnostic Testing in the US Hospitals, Commercial Laboratories and Point-of-Care/POC Locations

 
  • Category : Diagnostic and Biotech
  • Published On : August  2015
  • Pages : 635
 
 

Complete report $11,500.  DataPack (test volumes, sales forecasts, supplier shares) $7,500.


“2015-2019 Clinical Chemistry and Immunodiagnostics Testing in US Hospitals, Commercial Laboratories and Point-of-Care/POC Locations” is a new strategic analysis of major business opportunities emerging in the US clinical chemistry and immunodiagnostic hospital, commercial and point-of-care/POC markets during the next five years.  The report explores future trends in the US market; provides estimates of the specimen, test and sales volumes, as well as major suppliers’ sales and market shares; compares features of leading analyzers; profiles key competitors; and identifies specific product and marketing opportunities emerging during the next five years.


The report provides five-year volume and sales forecasts for over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein and abused drug assays performed in hospitals, commercial laboratories, physician offices,  ER, OR, ICU, cancer clinics, ambulatory care centers, surgery centers, nursing hones, and birth centers, including controls, calibrators and consumables.


Rationale


The clinical chemistry and immunodiagnostic markets are undergoing significant transformation, caused by convergence of new and more stringent regulations; advances in diagnostic technologies, system engineering, automation, and IT; and intensifying competition.  Some segments, like routine chemistry, are already resembling commodity markets, where product positioning and cost per test are more critical than underlying technology.  This evolving marketplace creates exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, and calibrators.


Strategic Recommendations


- New product development opportunities

with significant market appeal.


- Alternative market penetration strategies.


- Potential market entry barriers and risks.


Tests Analyzed in the Report


Routine Clinical Chemistry


Albumin, Alkaline Phosphatase, ALT/SGPT, Ammonia, Amylase, AST/SGOT, Bilirubin, Total,

BUN (Blood Urea Nitrogen), Calcium, Cardio CRP, Carbon Dioxide/Bicarbonate, Chloride,

Cholesterol, Creatine Kinase (CK), CK-MB, Creatinine, CRP, Ferritin, GGT, Glucose,

HDL Cholesterol, Homocysteine, Iron, LDH, LDL Cholesterol, Magnesium, Phosphorus,

Potassium, Protein, Total, Sodium, Triglycerides, Troponin, Uric Acid.


Therapeutic Drug Monitoring (TDM)


Amikacin, Carbamazepine, Cyclosporin, Digoxin, Everolimus, Gentamicin, Levetiracetam,

Lithium, Methotrexate, NAPA/Procainamide, Phenobarbital, Phenytoin, Quinidine, Sirolimus,

Tacrolimus, Theophylline, Tobramycin, Topirimate, Valproic Acid, Vancomycin.


Endocrine Function


Cortisol, Estradiol, FSH, HCG, Gastrin, LH, Progesterone, PTH/IO PTH,

Prolactin, T3, T3 Uptake,  Free T3, T4, Free T4, TBG, Testosterone,

Thyroglobulin Ab,  TPO Ab, TSH.


Tumor Markers and Special Chemistry


AFP, CA 15-3/27-29, CA 19-9, CEA, Ferritin, Follate (Folic Acid),

Glycosylated Hemoglobin, HCG, 25-Hydroxy Vitamin D2 and D3, Occult Blood,

PAP, PSA, Thyroglobulin, Vitamin B-12.


Immunoproteins


C3, C4, Free Light Chains, Haptoglobin, IgA, IgE Specific, IgE Total, IgG, IgM,

Immunofixation, Prealbumin, Protein Electrophoresis.


Drugs of Abuse


Amphetamines, Barbiturates, Benzodiazepines, Cannabinoids/Marijuana, Cocaine,

LSD, Methadone, Methaqualone, Opiates, Phencyclidine (PCP),

Propoxyphene, Tricyclic Antidepressants.


Market Segmentation Analysis


- Comprehensive review of the market

dynamics, trends, structure, size, growth,

and key suppliers.


- Test volume and sales forecasts for over 100 clinical chemistry,

TDM, endocrine, cancer, immunoprotein and abused drug assays,

by market segment:

    

Centralized Testing    

 

- Hospitals

- Commercial/Private Laboratories


POC/Decentralized Testing


- Physician Offices/Group Practices   

- Emergency Rooms       

- Operating/Recovery Suites     

- ICUs/CCUs

- Cancer Clinics       

- Ambulatory Care Centers       

- Surgery Centers

- Nursing Homes

- Birth Centers

   

Current and Emerging Products


- Analysis of current and emerging clinical chemistry

and immunodiagnostic tests.


- Review of current instrumentation technologies, and feature comparison

of high-, medium-, and low-volume/POC analyzers.


Technology Review


- Assessment of current and emerging

technologies, and their potential  market applications.


- Comprehensive lists of companies developing

or marketing new technologies and products by test.


Competitive Strategies


- Strategic assessments of major suppliers and

emerging market entrants, including their sales, product

portfolios, marketing tactics, collaborative

arrangements and new products in R&D. 


- The companies analyzed in the report include:


   - Abbott

   - AdnaGen

   - Agilent Technologies


   - Bayer Healthcare

   - Beckman Coulter/Danaher

   - Biomedical Diagnostics

   - Biomerieux

   - Bio-Rad

   - Diasorin

   - Eiken Chemical

   - Fujirebio

   - Grifols

   - Instrumentation Laboratory

   - Kyowa Medex

   - Matritech/Alere

   - Ortho-Clinical Diagnostics

   - Quest Diagnostics

   - Roche

   - Siemens

   - Sysmex

   - ThermoFisher

   - Tosoh

   - Wako

   - Wallac/PE


Contains 635 pages and 149 tables